Clinical trial
Pharmacogenomic Evaluation of Antihypertensive Responses
NCT00246519 · University of Florida, Other · Completed
Key facts
| NCT number | NCT00246519 |
|---|---|
| Title | Pharmacogenomic Evaluation of Antihypertensive Responses |
| Official title | Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) |
| Lead sponsor | University of Florida, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Hydrochlorothiazide, Atenolol |
| Enrollment | 1,701 |
| Start date | Oct 1, 2005 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Oct 31, 2005 |
| Last update posted | May 7, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: